PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $182,734 | -16.6% | 5,958 | +8.8% | 0.00% | – |
| Q2 2023 | $219,210 | -10.5% | 5,476 | -8.7% | 0.00% | – |
| Q1 2023 | $244,833 | -59.5% | 6,000 | -61.6% | 0.00% | -100.0% |
| Q4 2022 | $603,973 | -30.4% | 15,636 | -4.4% | 0.00% | -50.0% |
| Q3 2022 | $868,000 | -5.9% | 16,355 | +3.5% | 0.00% | 0.0% |
| Q2 2022 | $922,000 | -47.6% | 15,805 | -31.6% | 0.00% | -33.3% |
| Q1 2022 | $1,761,000 | +77.3% | 23,115 | +40.2% | 0.00% | +50.0% |
| Q4 2021 | $993,000 | +181.3% | 16,490 | +161.8% | 0.00% | +100.0% |
| Q3 2021 | $353,000 | -0.3% | 6,299 | +8.8% | 0.00% | 0.0% |
| Q2 2021 | $354,000 | -13.7% | 5,790 | -0.9% | 0.00% | 0.0% |
| Q1 2021 | $410,000 | +14.2% | 5,840 | -2.4% | 0.00% | 0.0% |
| Q4 2020 | $359,000 | -2.2% | 5,984 | -2.0% | 0.00% | 0.0% |
| Q3 2020 | $367,000 | +56.8% | 6,106 | +35.2% | 0.00% | 0.0% |
| Q2 2020 | $234,000 | +73.3% | 4,516 | +12.7% | 0.00% | 0.0% |
| Q1 2020 | $135,000 | – | 4,007 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GAGNON SECURITIES LLC | 563,415 | $21,753,453 | 4.80% |
| Gagnon Advisors, LLC | 180,331 | $6,962,579 | 4.70% |
| Spyglass Capital Management LLC | 868,686 | $33,539,966 | 2.69% |
| Tamarack Advisers, LP | 100,000 | $3,861,000 | 1.99% |
| ARMISTICE CAPITAL, LLC | 1,892,000 | $73,050,120 | 1.27% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 276,590 | $10,679,140 | 0.99% |
| RICE HALL JAMES & ASSOCIATES, LLC | 437,285 | $16,883,574 | 0.97% |
| Rock Springs Capital Management LP | 1,032,600 | $39,868,686 | 0.96% |
| OUTFITTER FINANCIAL LLC | 25,860 | $998,455 | 0.91% |
| Stephens Investment Management Group LLC | 1,168,469 | $45,535,237 | 0.82% |